Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations
Sign Up to like & getrecommendations! Published in 2024 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.50067
Abstract: Key Points Question Is adjuvant olaparib cost-effective in patients with early-stage breast cancer with high-risk disease and germline BRCA1/2 mutations? Findings In an economic evaluation using a Markov model, adjuvant olaparib therapy was associated with… read more here.
Keywords: breast cancer; adjuvant olaparib; germline brca1; olaparib ... See more keywords
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world database
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34304
Abstract: The outcomes and best treatment strategies for germline BRCA1/2 mutation (gBRCAm) carriers with metastatic breast cancer (MBC) remain uncertain. We compared the overall survival and the first line progression free survival (PFS1) of patients with… read more here.
Keywords: germline brca1; survival; status; metastatic breast ... See more keywords
Precursor fractions of neurotensin and enkephalin might point to molecular mechanisms of cancer risk modulation during a lifestyle-intervention in germline BRCA1/2 gene mutation carriers
Sign Up to like & getrecommendations! Published in 2021 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-020-06070-x
Abstract: Germline BRCA1/2 mutation carriers (gBMC) face increased cancer risks that are modulated via non-genetic lifestyle factors whose underlying molecular mechanisms are unknown. The peptides Neurotensin (NT) and Enkephalin (ENK)—involved in tumorigenesis and obesity-related diseases—are of… read more here.
Keywords: intervention; lifestyle intervention; mutation carriers; molecular mechanisms ... See more keywords
Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of cancer"
DOI: 10.1016/j.ejca.2020.12.007
Abstract: BACKGROUND BRCA1 and BRCA2 play a central role in DNA repair. Therefore, patients harbouring germline (g) BRCA1/2 mutations (m) treated with chemotherapy might be at higher risk of haematological toxicities. METHODS Patients from German Breast… read more here.
Keywords: chemotherapy; brca1; haematological toxicities; cancer ... See more keywords
Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2021.10.072
Abstract: BACKGROUND Histology restricted genetic predisposition testing of ovarian carcinoma patients is a topic of debate as the prevalence of BRCA1/2 pathogenic variants (PVs) in various histological subtypes is ambiguous. Our primary aim was to investigate… read more here.
Keywords: histological subtypes; brca1; ovarian carcinoma; germline brca1 ... See more keywords
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer
Sign Up to like & getrecommendations! Published in 2024 at "British Journal of Cancer"
DOI: 10.1038/s41416-024-02874-6
Abstract: High-grade serous ovarian cancer (HGSOC) can be treated with platinum-based neoadjuvant chemotherapy (NACT) and delayed primary surgery (DPS). Histopathological response to NACT can be assessed using Böhm’s chemotherapy response score (CRS). We investigated whether germline… read more here.
Keywords: cancer; germline brca1; response; chemotherapy ... See more keywords
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-16-2796
Abstract: Purpose: Rucaparib is a potent, oral, small-molecule PARP inhibitor. This phase I–II study was the first to evaluate single-agent oral rucaparib at multiple doses. Experimental Design: Part 1 (phase I) sought to determine the MTD,… read more here.
Keywords: brca1 mutated; rucaparib; parp inhibitor; phase study ... See more keywords
Incidence of germline BRCA1 and BRCA2 mutations among Filipinos.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e13628
Abstract: e13628Background: The Philippines has the highest reported incidence of breast cancer (BC) in Southeast Asia, with a rate of 47.7 per 100,000 per year. 5 to 10% of BC results from a hereditary pred... read more here.
Keywords: incidence; brca2 mutations; incidence germline; brca1 brca2 ... See more keywords
Evolution of germline BRCA1/2 testing practices: A five-year comparative analysis among oncology providers and patients.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e13172
Abstract: e13172 Background: The Association of Cancer Care Centers (ACCC) launched a quality improvement initiative in 2018 to address suboptimal germline BRCA1/2 testing rates and identify barriers impeding testing for patients with early-stage or metastatic breast… read more here.
Keywords: oncology; testing practices; cancer; brca1 testing ... See more keywords
Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.810099
Abstract: Background Whether neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) against primary debulking surgery (PDS) has a differential effect on prognosis due to Breast Cancer Susceptibility Genes (BRCA)1/2 mutations has not been confirmed by… read more here.
Keywords: cancer; study; germline brca1; neoadjuvant chemotherapy ... See more keywords
Prevalence of Germline BRCA1/2 Variants in Ashkenazi and Non-Ashkenazi Prostate Cancer Populations: A Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15010306
Abstract: Simple Summary Germline BRCA2 pathogenic variant carriers are associated with prostate cancer risk. Ashkenazi Jewish people are at higher risk of breast cancer due to the high prevalence of specific founder germline BRCA1/2 variants. The… read more here.
Keywords: prostate cancer; germline brca1; non ashkenazi; brca1 variants ... See more keywords